What got you to peak sales will not get you through maturity. After peak, growth comes from precision: the right healthcare professionals, the patient opportunities behind them, and an operating model sized for leaner budgets.
We help mature brands pursue a second growth curve, capturing 2 to 5% additional prescription opportunity while navigating the realities of where the brand is today.
2-5%
additional prescription opportunity from a mature brand
$2B+
baseline portfolio revenue across 11 brands
~250
rep equivalents a year delivered through Digital Rep Equivalence
After peak, three pressures arrive together. Growth stops being about reach: awareness is built, and success now depends on finding the right opportunities and executing with precision. The business gets leaner as complexity rises: budgets, field teams, and agency support may shrink while the pressure to deliver does not, so every investment carries more weight. And market conditions can move faster as competitors and generics reshape the category, increasing the need to stay visible and relevant where healthcare professionals make decisions.
As portfolio focus shifts toward newer assets, mature brands may operate with fewer resources even when meaningful revenue and prescription opportunity remains. The challenge is to protect that value without pulling resources away from growth brands.
A mature brand's broad healthcare professional universe often contains a smaller group with meaningful patient opportunity behind them. Growth at maturity means finding those healthcare professionals and engaging them with precision, at a cost the P&L can carry.
As opportunities become more concentrated, connecting healthcare professional behavior with patient and engagement signals becomes more important. Tandem, Indegene's omnichannel operating model, brings those signals together to help teams see where opportunity or share risk is changing.
Personal and non-personal channels working as one plan can extend coverage as field resources decline. Digital Rep Equivalence translates coordinated non-personal promotion into rep-equivalent and primary-detail-equivalent measures so teams can understand the coverage digital activity adds.
Cross-channel marketing mix read weeks after close gives way to more frequent healthcare professional-level incrementality against matched controls, with total and new-to-brand prescriptions informing the next cycle of targeting and spend.
As resources tighten, mature brands need to make sharper, faster decisions about where to invest, how to engage, and when to adjust. The second growth curve depends on that decision discipline.
Precision targeting on the Promotional Value Index uses healthcare professional-level scores spanning message affinity, channel affinity, promotional value, access and integrated delivery network affiliation, best time to engage, adoption speed, and patient opportunity. The goal is to focus investment where it can matter most.
Measure feeds Target. Every cycle sharpens the scores.
Proof
50%+
engagement above forecast
11.16%
increase in prescriptions
12:1
return on investment
See how a KOL-led omnichannel program connected patient-care insights across digital and field channels to improve engagement and prescribing.
Explore how paid media can extend priority content, strengthen reach, and work more effectively as part of a connected omnichannel program.
Learn how strategy, data, content, activation, and measurement can work together to support more responsive commercial decisions.
Tandem brings together healthcare professional behavior, engagement history, access, affinity, and other relevant signals to identify opportunity and risk.
Commercial scoring that helps prioritize the healthcare professionals and patient opportunities where continued investment can matter most.
Journeys, content, and channels planned as one coordinated system under human strategic direction, with new creative and modular content moving through medical, legal, and regulatory review.
Coordinated cross-channel engagement translated into rep equivalents and primary detail equivalents to help teams understand and extend coverage.
Healthcare professional-level performance, incrementality, and prescription outcomes that inform ongoing targeting and investment decisions.
Commercial support through loss of exclusivity, including broader execution responsibility and shared-economics models where appropriate.
The second growth curve is the additional prescription and revenue opportunity a mature brand can pursue by focusing investment on the healthcare professionals, patients, and markets where meaningful opportunity remains.
The model combines precision targeting, efficient coverage, and ongoing measurement as the brand moves toward loss of exclusivity.
Digital Rep Equivalence measures coordinated non-personal engagement in terms commercial teams already use: rep equivalents and primary detail equivalents.
It helps teams understand how digital activity can extend coverage and complement field engagement.
Tandem is Indegene's omnichannel operating model, bringing together people, tools, data, and technology.
It connects healthcare professional behavior, engagement history, access, affinity, and other relevant signals to guide targeting and activation decisions.
Co-commercialization is a partnership model in which Indegene can take broader responsibility for commercial execution and, where appropriate, align economics with the brand's performance.
The model is tailored to the needs and stage of the portfolio.
Bring us one mature brand's P&L, performance data, and current commercial model. We will identify where prescription and revenue opportunity may remain, which healthcare professionals and markets deserve continued investment, and what operating model can support the next phase of the brand.